Publications by authors named "Susan L Ellard"

Claim this Profile
T
The impact of erythropoiesis-stimulating agents administration concomitantly with adjuvant anti-HER2 treatments on the outcomes of patients with early breast cancer: a sub-analysis of the ALTTO study.
Diogo Martins-Branco, Marie Kassapian, Véronique Debien, Rafael Caparica, Daniel Eiger, Susan L Ellard

Breast Cancer Res Treat· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
What if the future of HER2-positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study.
Sara Pizzamiglio, Giulia Cosentino, Chiara M Ciniselli, Loris De Cecco, Alessandra Cataldo, Susan L Ellard

Cancer Med· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Niraparib for Advanced Breast Cancer with Germline and Mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO Study.
Nicholas C Turner, Judith Balmaña, Coralie Poncet, Theodora Goulioti, Konstantinos Tryfonidis, Susan L Ellard

Clin Cancer Res· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial.
Stephanie Lheureux, Mihaela C Cristea, Jeffrey P Bruce, Swati Garg, Michael Cabanero, Susan L Ellard

Lancet· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial.
Daniel J Khalaf, Matti Annala, Sinja Taavitsainen, Daygen L Finch, Conrad Oja, Susan L Ellard

Lancet Oncol· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Utilizing RE-AIM to examine the translational potential of Project MOVE, a novel intervention for increasing physical activity levels in breast cancer survivors.
Tanya Pullen, Joan L Bottorff, Catherine M Sabiston, Kristin L Campbell, Neil D Eves, Susan L Ellard

Transl Behav Med· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205.
Sebastien J Hotte, Kim N Chi, Anthony M Joshua, Donsheng Tu, Robyn J Macfarlane, Susan L Ellard

Clin Genitourin Cancer· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A preliminary trial examining a 'real world' approach for increasing physical activity among breast cancer survivors: findings from project MOVE.
Cristina M Caperchione, Catherine M Sabiston, Sean Stolp, Joan L Bottorff, Kristin L Campbell, Susan L Ellard

BMC Cancer· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancer.
Evan Y Yu, Susan L Ellard, Sebastien J Hotte, Joel R Gingerich, Anthony M Joshua

Invest New Drugs· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acceptability and satisfaction of project MOVE: A pragmatic feasibility trial aimed at increasing physical activity in female breast cancer survivors.
Tanya Pullen, Paul Sharp, Joan L Bottorff, Catherine M Sabiston, Kristin L Campbell, Susan L Ellard

Psychooncology· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer.
Stephen K Chia, Susan L Ellard, Mihaela Mates, Stephen Welch, Catalin Mihalcioiu

Breast Cancer Res· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Innovative approach for increasing physical activity among breast cancer survivors: protocol for Project MOVE, a quasi-experimental study.
Cristina M Caperchione, Catherine M Sabiston, Marianne I Clark, Joan L Bottorff, Renee Toxopeus, Susan L Ellard

BMJ Open· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer.
Daniel Rayson, Sasha Lupichuk, Kylea Potvin, Susan Dent, Tamara Shenkier, Susan L Ellard

Breast Cancer Res Treat· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Ventricular-Arterial Coupling in Breast Cancer Patients After Treatment With Anthracycline-Containing Adjuvant Chemotherapy.
Graeme J Koelwyn, Nia C Lewis, Susan L Ellard, Lee W Jones, Jinelle C Gelinas

Oncologist· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.
Karen A Gelmon, Frances M Boyle, Bella Kaufman, David G Huntsman, Alexey Manikhas, Susan L Ellard

J Clin Oncol· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naïve castration-resistant prostate cancer.
Arun A Azad, Emma K Beardsley, Sebastian J Hotte, Susan L Ellard, Lawrence Klotz

Invest New Drugs· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer.
Elizabeth Maunsell, Paul E Goss, Rowan T Chlebowski, James N Ingle, José E Alés-Martínez, Susan L Ellard

J Clin Oncol· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer.
Emma K Beardsley, Sebastien J Hotte, Scott North, Susan L Ellard, Eric Winquist

Invest New Drugs· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of novel therapeutic targets in microdissected clear cell ovarian cancers.
Michael P Stany, Vinod Vathipadiekal, Laurent Ozbun, Rebecca L Stone, Samuel C Mok, Susan L Ellard

PLoS One· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abiraterone and increased survival in metastatic prostate cancer.
Johann S de Bono, Christopher J Logothetis, Arturo Molina, Karim Fizazi, Scott North, Susan L Ellard

N Engl J Med· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163.
Susan L Ellard, Mark Clemons, Karen A Gelmon, Brian Norris, Hagen Kennecke

J Clin Oncol· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of a letter notification program for women with early-stage breast cancer eligible for extended adjuvant letrozole.
Heather L McArthur, Karen A Gelmon, Ivo A Olivotto, Caroline H Speers, Susan L Ellard

J Clin Oncol· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis